|
|
| | Benzamide, 5-chloro-N-[5-chloro-4-[(4-chlorophenyl)cyanomethyl]-2-methylphenyl]-2-hydroxy- Basic information |
| | Benzamide, 5-chloro-N-[5-chloro-4-[(4-chlorophenyl)cyanomethyl]-2-methylphenyl]-2-hydroxy- Chemical Properties |
| Boiling point | 538.7±50.0 °C(Predicted) | | density | 1.442±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 125 mg/mL (280.44 mM) | | form | Solid | | pka | 7+-.0.43(Predicted) | | color | White to off-white |
| | Benzamide, 5-chloro-N-[5-chloro-4-[(4-chlorophenyl)cyanomethyl]-2-methylphenyl]-2-hydroxy- Usage And Synthesis |
| Uses | ZT-1a is a potent, non-ATP-competitive and selective SPAK inhibitor. ZT-1a inhibits SPAK activity with IC50s of 44.3, 35.0, 46.7 μM at ATP concentrations of 0.01, 0.1 and 1 mM, respectively[1]. | | in vivo | ZT-1a (10-100 mg/kg) inhibits SPAK-dependent cation-Cl cotransporters (CCC) phosphorylation in vivo[1]. | Animal Model: | Naive mice[1] | | Dosage: | 10, 30, 50, and 100mg/kg | | Administration: | Intraperitoneal (i.p.) administration | | Result: | Inhibited SPAK-dependent cation-Cl- cotransporters (CCC) phosphorylation in vivo. |
| | References | [1] Jinwei Zhang, et al. Modulation of Brain cation-Cl- Cotransport via the SPAK Kinase Inhibitor ZT-1a. Nat Commun. 2020 Jan 7;11(1):78. DOI:10.1038/s41467-019-13851-6 |
| | Benzamide, 5-chloro-N-[5-chloro-4-[(4-chlorophenyl)cyanomethyl]-2-methylphenyl]-2-hydroxy- Preparation Products And Raw materials |
|